The first study, Ipsos global obesity & cardiometabolic disease therapy monitor, will offer treatment data on patients receiving anti-obesity medications, alongside data on perceptions of treating healthcare professionals (HCPs).

A parallel consumer study will monitor users’ experiences of such medications and uncover the evolving attitudes and behaviour of those who are eligible for treatment, and the general population, around these drugs and health in general.

The survey will focus on areas including understanding of obesity, reasons for or against engaging with HCPs and awareness of and experiences with anti-obesity medications. It will also monitor whether these treatments are reducing consumption in food and beverage categories.

A third study will focus on market sizing, measuring the current and likely future utilisation of the GLP-1 RAs drug class – both within obesity and for other conditions such as congestive heart failure and chronic kidney disease.

Ipsos will run the studies multiple times per year, with data available to multiple subscribers.

Roberto Cortese, senior director of Ipsos’ healthcare syndicated services portfolio, said the studies would allow Ipsos to inform clients about “the deeper treatment dynamics happening across the cardiometabolic space”.

Ramya Logendra, director of Ipsos’ healthcare syndicated services portfolio, added: “With anti-obesity medications poised to impact not just healthcare systems but lifestyles and consumption habits in general, these studies can inform the strategies of multiple stakeholders beyond pharma – including healthcare bodies, the food and beverage industry, retailers, the public sector, and others.”